Orbimed Advisors portfolio
Investment firmPortfolio as of Jun 30, 2026 (Q2 2026) · filed with the SEC on Aug 14, 2026 · data updated on Nov 5, 2026 · Q2 2026 13F (filing) ↗ · all its 13F filings ↗
A 13F shows the portfolio at quarter-end and is filed up to 45 days later: these are not real-time positions and they may have changed.
Orbimed Advisors reported a $5.3 bn portfolio of 117 positions to the SEC as of the end of Q2 2026. Its largest positions are EWTX, ELVN, LLY. During the quarter it opened UnitedHealth Group and Humana and exited Pfizer and Danaher.
Sections with a free account
What it reported after the quarter end (Q2 2026)
The 13F shows the portfolio as of Jun 30, 2026. Since then Orbimed Advisors has filed these own trades with the SEC (Form 4, when it owns more than 10% of a company or holds a role in it) and stakes above 5% (13D and 13G). It is not everything it did: only what it must report before the next 13F.
Form 4 · 85,918 shares · trade of Jul 7 · filed Jul 9, 2026 · filing ↗
Stake reported in the company · event of Oct 6, 2026 · filed Oct 8, 2026 · filing ↗
- 13DAdarx Pharmaceuticals14 %
Stake reported in the company · event of Sep 28, 2026 · filed Oct 2, 2026 · filing ↗
- 13DElectra Therapeutics11 %
Stake reported in the company · event of Sep 21, 2026 · filed Sep 25, 2026 · filing ↗
- 13D/ABraveheart Bio17.2 % → 13.5 %
Stake reported in the company · event of Sep 8, 2026 · filed Sep 10, 2026 · filing ↗
- 13DBlossomhill Therapeutics8.9 %
Stake reported in the company · event of Aug 10, 2026 · filed Aug 18, 2026 · filing ↗
Stake reported in the company · event of Aug 6, 2026 · filed Aug 10, 2026 · filing ↗
- 13DYarrow Bioscience10 %
Stake reported in the company · event of Jul 27, 2026 · filed Aug 5, 2026 · filing ↗
Plus 9 more, in its EDGAR filings.
What changed this quarter
107 positions with a change (30 new, 33 added to, 26 trimmed, 18 sold); also, 1 entered through an IPO, 1 exited through an acquisition or merger. 12 are listed here: those of 0.5 points of the portfolio or more (up to 12).
- Newly listedOdyssey TherapeuticsODTX1.1% of the portfolio
It started trading this quarter: it appears in a 13F for the first time. The filing does not say whether the manager already held it before the listing, so it is not counted as a purchase.
- UnitedHealth Group+1.3 ppof portfolioNew— → 1.3%
- Humana+1.2 ppof portfolioNew— → 1.2%
- Enliven Therapeutics−15%fewer sharesReduced7.1% → 6.5%
- Pfizer−1.0 ppof portfolioSold out1.2% → —
- Arcutis Biotherapeutics+1.0 ppof portfolioNew— → 1.0%
- Cogent Biosciences+422%more sharesIncreased0.3% → 1.2%
- Disc Medicine−67%fewer sharesReduced1.5% → 0.5%
- Danaher−1.0 ppof portfolioSold out1.1% → —
- Astrazeneca+37%more sharesIncreased3.0% → 3.2%
- Sionna Therapeutics−28%fewer sharesReduced3.2% → 2.1%
- Argenx−32%fewer sharesReduced2.3% → 1.6%
- Structure Therapeutics+50%more sharesIncreased1.6% → 2.3%
The figure on the right: for positions added to or trimmed, the change in the number of shares (%); for new and sold ones, the points of the portfolio moved (pp). Below, the portfolio weight before → after. Traded weight: what it bought or sold, excluding price effects.
Top holdings
- Edgewise TherapeuticsEWTX12.0%
- Enliven TherapeuticsELVN6.5%
- Eli LillyLLY5.9%
- MBX BiosciencesMBX3.6%
- Sinovac BiotechSVA3.5%
- AstrazenecaAZN3.2%
- Structure TherapeuticsGPCR2.3%
- Sionna TherapeuticsSION2.1%
- Corvus PharmaceuticalsCRVS2.0%
- Arrivent BiopharmaAVBP2.0%
- Guardant HealthGH1.7%
- ArgenxARGX1.6%
- MerckMRK1.6%
- uniQureQURE1.6%
- Praxis Precision MedicinesPRAX1.5%
“Since”: first quarter of the current run, unbroken until today. In the details, prices are the quarter-end prices of the quarters in which it added shares, per the 13F. The manager may have bought at any price within each quarter; the SEC only publishes the value at quarter end.
Portfolio by sector
- ● Health Care 99%
- ● No sector 1%
How its portfolio changed (8 quarters)
Q2 2026: 117
Q2 2026: 43%
Q2 2026: 15.4%
Traded turnover: the weight it bought plus the weight it sold in the quarter, divided by two, excluding price moves. The plain “turnover” in the header does include that effect. With a free account: the full history and sectors over time.
Declared options (8)
Besides stocks, Orbimed Advisors declared 2 puts (they gain if the stock falls) and 6 calls (they gain if it rises) with a notional of $117M. The 13F reports the value of the underlying shares, not the premium paid, so these figures look large and are not added to the portfolio. Nor does it say whether the option is bought or written, or its strike or expiry: it may be a hedge.
- PUTState Street SPDR S&P Biotech ETFXBInew this quarter$47.5M
- CALLAbivaxABVXnew this quarter$26.7M
- CALLProtagonist TherapeuticsPTGXnew this quarter$18.4M
- CALLRevolution MedicinesRVMDnew this quarter$9.4M
- CALLPalvella TherapeuticsPVLA$6.1M
- CALLUnitedHealth GroupUNHnew this quarter$4.2M
- CALLElevance HealthELVnew this quarter$3.9M
- PUTSELLAS Life Sciences GroupSLSnew this quarter$1.4M
Stakes above 5% (13D/13G)
Companies where this filer reported holding 5% or more of the shares. It is the figure from its latest filing on each one; history since December 2024.
How we classify it
Investment firm, per its Form ADV of Aug 18, 2026 (medium confidence).
The data, as reported: ORBIMED ADVISORS LLC (CRD 118608): 7.B private funds: 5 hedge, 5 pe, 14 other (gross assets $19.0 bn); 5.D assets by client type: pooled vehicles 100% (of $20.6 bn)
The type comes from a rule applied to that data. If it looks wrong, tell us.
Not counted as a concentrated manager: its portfolio is not within 5 to 100 positions; its top 10 positions are under 45%. Its portfolio is shown all the same, but it is left out of manager counts, the consensus and the ranking. How this is decided
Similar managers by type and size
Same type of filer and a 13F portfolio value between a third and three times this one. It is not a comparison of what they hold.
- Paradigm Biocapital AdvisorsInvestment firm · $5.3 bn
- Skye Global ManagementInvestment firm · $5.1 bn
- Baupost GroupInvestment firm · $5.4 bn
- Akre Capital ManagementInvestment firm · $5.1 bn
- Resolution CapitalInvestment firm · $5.4 bn
- Maple Rock Capital PartnersInvestment firm · $5.1 bn